222 related articles for article (PubMed ID: 35207518)
1.
Salleh MZ; Deris ZZ
Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
[TBL] [Abstract][Full Text] [Related]
2. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
[TBL] [Abstract][Full Text] [Related]
3. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
6. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
[TBL] [Abstract][Full Text] [Related]
7. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
[TBL] [Abstract][Full Text] [Related]
9. Targeting mechanism for SARS-CoV-2
Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
[TBL] [Abstract][Full Text] [Related]
10. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
[TBL] [Abstract][Full Text] [Related]
11.
Schönfelder K; Breuckmann K; Elsner C; Dittmer U; Fistera D; Herbstreit F; Risse J; Schmidt K; Sutharsan S; Taube C; Jöckel KH; Siffert W; Kribben A; Möhlendick B
Front Genet; 2021; 12():667231. PubMed ID: 33968142
[TBL] [Abstract][Full Text] [Related]
12. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
Kumar V; Dhanjal JK; Bhargava P; Kaul A; Wang J; Zhang H; Kaul SC; Wadhwa R; Sundar D
J Biomol Struct Dyn; 2022 Jan; 40(1):1-13. PubMed ID: 32469279
[TBL] [Abstract][Full Text] [Related]
13. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture.
Wettstein L; Knaff PM; Kersten C; Müller P; Weil T; Conzelmann C; Müller JA; Brückner M; Hoffmann M; Pöhlmann S; Schirmeister T; Landfester K; Münch J; Mailänder V
Commun Biol; 2022 Jul; 5(1):681. PubMed ID: 35804152
[TBL] [Abstract][Full Text] [Related]
14. Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies.
M P; Reddy GJ; Hema K; Dodoala S; Koganti B
Eur J Pharmacol; 2021 Jan; 890():173688. PubMed ID: 33130280
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
Shakya A; Chikhale RV; Bhat HR; Alasmary FA; Almutairi TM; Ghosh SK; Alhajri HM; Alissa SA; Nagar S; Islam MA
Mol Divers; 2022 Feb; 26(1):265-278. PubMed ID: 33786727
[TBL] [Abstract][Full Text] [Related]
16. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
[TBL] [Abstract][Full Text] [Related]
17. Computational screening of phytochemicals from three medicinal plants as inhibitors of transmembrane protease serine 2 implicated in SARS-CoV-2 infection.
Oyedara OO; Agbedahunsi JM; Adeyemi FM; Juárez-Saldivar A; Fadare OA; Adetunji CO; Rivera G
Phytomed Plus; 2021 Nov; 1(4):100135. PubMed ID: 35403085
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions.
Hussain M; Jabeen N; Amanullah A; Baig AA; Aziz B; Shabbir S; Raza F; Uddin N
AIMS Microbiol; 2020; 6(3):350-360. PubMed ID: 33029570
[TBL] [Abstract][Full Text] [Related]
19. Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19.
Sharma T; Baig MH; Khan MI; Alotaibi SS; Alorabi M; Dong JJ
Saudi Pharm J; 2022 Mar; 30(3):217-224. PubMed ID: 35095307
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.
Vardhan S; Sahoo SK
J Tradit Complement Med; 2022 Jan; 12(1):6-15. PubMed ID: 33868970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
